333 related articles for article (PubMed ID: 33893632)
1. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
Favaloro EJ; Henry BM; Lippi G
Semin Thromb Hemost; 2021 Jun; 47(4):400-418. PubMed ID: 33893632
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period.
Katneni UK; Ibla JC; Hunt R; Schiller T; Kimchi-Sarfaty C
J Thromb Haemost; 2019 Mar; 17(3):429-440. PubMed ID: 30593735
[TBL] [Abstract][Full Text] [Related]
3. The role of ADAMTS-13 in the coagulopathy of sepsis.
Levi M; Scully M; Singer M
J Thromb Haemost; 2018 Apr; 16(4):646-651. PubMed ID: 29337416
[TBL] [Abstract][Full Text] [Related]
4. Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus.
Katneni UK; Alexaki A; Hunt RC; Schiller T; DiCuccio M; Buehler PW; Ibla JC; Kimchi-Sarfaty C
Thromb Haemost; 2020 Dec; 120(12):1668-1679. PubMed ID: 32838472
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
Ward SE; Fogarty H; Karampini E; Lavin M; Schneppenheim S; Dittmer R; Morrin H; Glavey S; Ni Cheallaigh C; Bergin C; Martin-Loeches I; Mallon PW; Curley GF; Baker RI; Budde U; O'Sullivan JM; O'Donnell JS;
J Thromb Haemost; 2021 Aug; 19(8):1914-1921. PubMed ID: 34053187
[TBL] [Abstract][Full Text] [Related]
6. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
[TBL] [Abstract][Full Text] [Related]
7. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Karakaya B; Tombak A; Serin MS; Tiftik N
Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
[TBL] [Abstract][Full Text] [Related]
9. Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease.
Hunt R; Hoffman CM; Emani S; Trenor CC; Emani SM; Faraoni D; Kimchi-Sarfaty C; Ibla JC
J Thromb Haemost; 2017 Dec; 15(12):2306-2316. PubMed ID: 28981194
[TBL] [Abstract][Full Text] [Related]
10. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
[TBL] [Abstract][Full Text] [Related]
11. Thrombosis and von Willebrand Factor.
Shahidi M
Adv Exp Med Biol; 2017; 906():285-306. PubMed ID: 27628010
[TBL] [Abstract][Full Text] [Related]
12. An Overview of Laboratory Testing for ADAMTS13.
Favaloro EJ; Pasalic L
Methods Mol Biol; 2023; 2663():481-486. PubMed ID: 37204731
[TBL] [Abstract][Full Text] [Related]
13. Secretion of von Willebrand Factor and Suppression of ADAMTS-13 Activity by Markedly High Concentration of Ferritin.
Bashir DA; Da Q; Pradhan S; Sekhar N; Valladolid C; Lam F; Guffey D; Goldman J; Desai MS; Cruz MA; Allen C; Nguyen TC; Vijayan KV
Clin Appl Thromb Hemost; 2021; 27():1076029621992128. PubMed ID: 33539188
[TBL] [Abstract][Full Text] [Related]
14. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
Zhou Z; Nguyen TC; Guchhait P; Dong JF
Semin Thromb Hemost; 2010 Feb; 36(1):71-81. PubMed ID: 20391298
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
Schwaegermann MK; Hobohm L; Rausch J; Reuter M; Griemert TF; Sivanathan V; Falter T; Sprinzl MF; Lackner KJ; Galle PR; Konstantinides S; Theobald M; von Auer C
Hamostaseologie; 2023 Jun; 43(3):215-218. PubMed ID: 34327693
[TBL] [Abstract][Full Text] [Related]
17. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.
Dong JF; Moake JL; Nolasco L; Bernardo A; Arceneaux W; Shrimpton CN; Schade AJ; McIntire LV; Fujikawa K; López JA
Blood; 2002 Dec; 100(12):4033-9. PubMed ID: 12393397
[TBL] [Abstract][Full Text] [Related]
18. The potential therapeutic benefit of targeting ADAMTS13 activity.
Eerenberg ES; Levi M
Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607
[TBL] [Abstract][Full Text] [Related]
19. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.
Lattuada A; Rossi E; Calzarossa C; Candolfi R; Mannucci PM
Haematologica; 2003 Sep; 88(9):1029-34. PubMed ID: 12969811
[TBL] [Abstract][Full Text] [Related]
20. von Willebrand factor, von Willebrand factor-cleaving protease, and shear stress.
Perutelli P; Molinari AC
Cardiovasc Hematol Agents Med Chem; 2007 Oct; 5(4):305-10. PubMed ID: 17979694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
